Literature DB >> 25030957

[Pathological fractures due to malignant bone tumors].

M Schultheiss1, S E Traub, A v Baer.   

Abstract

BACKGROUND: Malignant bone tumors should be treated within interdisciplinary treatment concepts. The prognosis of pathological fractures is on the whole relatively poor because the fracture is indicative of a large and highly aggressive tumor and the hematoma associated with the fracture could possibly result in spreading of the tumor into the surrounding soft tissues.
OBJECTIVES: This article summarizes the current interdisciplinary treatment concepts under special consideration of pathological fractures in primary bone tumors.
METHODS: A selective literature search was carried out taking own experience into consideration.
RESULTS: Due to the multimodal therapy approach for osteosarcoma and Ewing's sarcoma, the 5-year survival rate could be increased to 60-70 %.
CONCLUSION: The therapeutic treatment should always be carried out within the framework of an interdisciplinary, oncological bone expert team, especially in cases of pathological fractures of malignant bone tumors.

Entities:  

Mesh:

Year:  2014        PMID: 25030957     DOI: 10.1007/s00113-013-2474-2

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  10 in total

Review 1.  Ewing sarcoma: clinical state-of-the-art.

Authors:  Jenny Potratz; Uta Dirksen; Heribert Jürgens; Alan Craft
Journal:  Pediatr Hematol Oncol       Date:  2012-02       Impact factor: 1.969

2.  Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life.

Authors:  G Bacci; S Ferrari; D Donati; A Longhi; F Bertoni; M Di Fiore; A Comandone; M Cesari; M Campanacci
Journal:  Oncol Rep       Date:  1998 Sep-Oct       Impact factor: 3.906

3.  Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial.

Authors:  H Jürgens; U Exner; H Gadner; D Harms; J Michaelis; R Sauer; J Treuner; T Voûte; W Winkelmann; K Winkler
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

4.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

Review 5.  [Pathological fractures].

Authors:  W Mutschler; R Wirbel
Journal:  Unfallchirurg       Date:  1997-06       Impact factor: 1.000

6.  Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80.

Authors:  M Salzer-Kuntschik; G Delling; G Beron; R Sigmund
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

7.  Controversies in childhood osteosarcoma.

Authors:  S Bielack; B Kempf-Bielack; T Von Kalle; R Schwarz; T Wirth; L Kager; J Whelan
Journal:  Minerva Pediatr       Date:  2013-04       Impact factor: 1.312

Review 8.  Common musculoskeletal tumors of childhood and adolescence.

Authors:  Carola A S Arndt; Peter S Rose; Andrew L Folpe; Nadia N Laack
Journal:  Mayo Clin Proc       Date:  2012-05       Impact factor: 7.616

9.  Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures.

Authors:  H Mirels
Journal:  Clin Orthop Relat Res       Date:  1989-12       Impact factor: 4.176

10.  Dedifferentiated chondrosarcoma.

Authors:  M Mercuri; P Picci; L Campanacci; E Rulli
Journal:  Skeletal Radiol       Date:  1995-08       Impact factor: 2.199

  10 in total
  1 in total

1.  Meta-analysis of the prognosis after surgical treatment of osteosarcoma complicated by pathologic fracture.

Authors:  Wei Zhong; Ziyi Wu; Yuhao Yuan; Wei Luo
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.